At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy, discusses the median progression-free survival (PFS) evaluation and correlative biomarker analysis from coBRIM, a phase 3 study of cobimetinib plus vemurafenib in patients with advanced BRAF-mutated melanoma.
